NCT00893217已完成2 期
Double-blind, Randomized, Parallel Group, Multicenter Study of the Safety and Tolerability of Betaseron 500 Mcg Subcutaneously Every Other Day and Betaseron 250 Mcg Subcutaneously Every Other Day for at Least 12 Weeks in Patients With RRMS
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 71
- 主要终点
- To evaluate the safety and tolerability of IFNB-1b 500 mcg given subcutaneously (SC) QOD compared with the standard dose of 250 mcg QOD in patients with RRMS.
研究概览
简要总结
The purpose of this study is to valuate safety and tolerability of Betaseron.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of RRMS as defined by any of the following McDonald diagnostic criteria (McDonald et al 2001; see Appendix 16.1.1 [(Protocol Appendix 5]):
- •Two relapses and objective clinical evidence (history or present) of at least 2 lesions
- •Two relapses and objective clinical evidence (history or present) of 1 lesion; and dissemination in space, demonstrated by MRI (Barkhof/Tintoré criteria) or 2 MRI T2 lesions consistent with MS plus positive CSF.
- •One relapse with objective clinical evidence (history or present) of at least 2 lesions, and dissemination in time, demonstrated signs of disease activity ( new Gd+ lesion or new T2 lesion) in an MRI scan at least 3 months after the onset of that clinical event.
- •One relapse and objective clinical evidence (history or present) of 1 lesion, and dissemination in space, demonstrated by MRI (Barkhof/Tintoré criteria); or 2 MRI T2 lesions consistent with MS plus positive CSF, and dissemination in time, demonstrated by signs of disease activity (new Gd+ lesion or new T2 lesion) in an MRI scan at least 3 months after the onset of that clinical event.
- •18 to 55 years of age
- •Score of 0-5.5 on the Kurtzke Expanded Disability Status Scale' (EDSS; see Appendix 16.1.1 [Protocol Appendix 4])
- •Naïve to immunomodulating therapies or previously treated with immunomodulating therapies other than any interferon (IFN) more than 30 days prior to the start of the study
- •If female of child-bearing potential, agreement to practice adequate contraception methods (IUCD, condoms, oral contraceptives, or other adequate barrier contraception)
- •Negative serum pregnancy test results.
- •Signed and dated statement of informed consent
排除标准
- •Clinically significant heart disease such as uncontrolled cardiac dysrhythmia, angina pectoris, cardiomyopathy, or congestive heart failure
- •History of severe depression, suicide attempts, or current suicidal ideations
- •Clinically significant liver, renal, and bone marrow dysfunction as defined by any of the following laboratory evaluations:
- •bone marrow dysfunction:
- •Hb <8.5 g/dl
- •WBC <2.5 x 109/L
- •platelet count <125 x 109/L
- •renal dysfunction: creatinine >1.8 mg/dL
- •liver dysfunction:
- •ASAT (SGOT) >3xupper limit of normal
- •bilirubin >2x upper limit of normal
- •Epilepsy not adequately controlled by treatment
- •Any conditions that could interfere with the MRI or any other evaluation in the study
- •Known allergy to human proteins including albumin and IFN, or to mannitol or gadolinium
- •Participation in any clinical study within the past 30 days or use/intake of an investigational drug within the last 3 months prior to study entry
- •Prior treatment with monoclonal antibody therapy, cladribine or total lymphoid irradiation
- •Treatment with cytotoxic or immunosuppressive therapies (except systemic steroid or adrenocorticotropic hormone [ACTH]) within 6 months prior to study entry; or systemic steroid or ACTH within 1 month prior to study entry
- •Presence of monoclonal gammopathy
- •Inability to tolerate both NSAIDs and acetaminophen
- •Pregnancy or lactation
- •History of alcohol or drug abuse
- •Inability to administer subcutaneous injections either by self or by caregiver
- •Medical, psychiatric or other conditions that compromise the patient's ability to give informed consent, to understand the patient information, to comply with the study protocol, or to complete the study
研究组 & 干预措施
Arm 1
Active Comparator
干预措施: Betaseron (Interferon beta-1b, BAY86-5046) (Drug)
Arm 2
Experimental
干预措施: Betaseron (Interferon beta-1b, BAY86-5046) (Drug)
结局指标
主要结局
To evaluate the safety and tolerability of IFNB-1b 500 mcg given subcutaneously (SC) QOD compared with the standard dose of 250 mcg QOD in patients with RRMS.
时间窗: 8 Months
次要结局
未报告次要终点
研究者
相似试验
已完成
4 期
An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MSMultiple Sclerosis, Relapsing-RemittingNCT00206648Bayer271
已完成
3 期
BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) PatientsMultiple Sclerosis, Relapsing-RemittingNCT00099502Bayer2,244
已完成
1 期
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ABT-652 in Subjects With Excessive Daytime SleepinessSleep DisorderNCT01124851Abbott36
进行中（未招募）
2 期
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)Heart FailureNCT06122779Bristol-Myers Squibb227
招募中
不适用
Impact of Beta-blocker on Outcome Among Patients Undergoing Transcatheter Aortic Valve Replacement (B-TAVR)Aortic StenosisNCT06472934University Hospital, Basel, Switzerland498